General Atlantic is building its position just as Pharvaris nears pivotal readouts. This article breaks down what the fund may be anticipating and the signals investors should track next.General Atlantic, L.P. disclosed a purchase of 500,000 additional shares of Pharvaris (PHVS 7.23%), boosting its position by an estimated $67.83 million, per November 13, 2025, SEC filing.What happenedAccording to a filing with the Securities and Exchange Commission (SEC) dated November 13, 2025, General Atlantic, L.P. acqu ...

Core Insights - Pharvaris N.V. is focused on developing innovative oral therapies for rare diseases, particularly hereditary angioedema (HAE) [3][2] - The company operates a clinical-stage biopharmaceutical model, investing in research and development to advance its pipeline through regulatory milestones for future commercialization [1][3] Company Overview - Pharvaris N.V. develops small molecule therapies for HAE, including PHA121, PHVS416, and PHVS719 [2] - The company leverages proprietary small molecule technology to address significant unmet medical needs in the rare disease space [3] Financial Performance - As of November 14, 2025, shares of Pharvaris N.V. were priced at $23.55, reflecting a 14.6% increase over the past year, outperforming the S&P 500 by 5.01 percentage points [4] - Bain Capital Life Sciences Investors, LLC sold 122,106 shares of Pharvaris N.V. during the third quarter, reducing its position value by $21.23 million, with remaining shares valued at $79.37 million [5][6] Market Context - Pharvaris stock has increased over 50% in the last six months, nearing its 52-week high of $26.33 [8] - Despite the sale of shares by Bain Capital, the total value of its Pharvaris stock increased from approximately $58 million at the end of Q2 to $79 million at the end of Q3 [9]